Startup Deep Dive : Curadev Pharma — Noida biotech that licensed cancer drugs to Roche for up to $555 million

In April 2015, a little-known drug-discovery company working out of Noida signed a deal that most Indian biotech founders only dream about: Roche agreed to pay it $25 million (about ₹240 crore) up front, with up to $530 million more in milestones, for the worldwide rights to a single experimental cancer molecule. Add it up and the pact was headlined at up to $555 million, roughly ₹5,300 crore at today’s exchange rate. That was Curadev Pharma.

Here is the contradiction that defines Curadev. For all those nine-figure deal headlines with Roche, Bayer and Takeda, the company itself booked operating revenue of just ₹14.1 crore (about $1.5 million) in the year to March 2025, as per data aggregator Tracxn. Curadev is not a business that sells medicine. It is a business that sells the science before the medicine exists, and understanding the gap between those two numbers is the whole story of how deep-tech drug discovery actually makes money in India.

Quick facts

What Curadev actually does

Curadev is a small-molecule drug-discovery company. It designs chemical compounds that switch cancer-related biological pathways on or off, takes them through pre-clinical testing, and then either licenses them to a large pharmaceutical partner or, more recently, carries them into early human trials itself. The therapeutic focus, per the company and multiple profiles, is immuno-oncology and inflammation, built around two families of targets:

• The kynurenine pathway — the IDO1 and TDO enzymes that tumours use to suppress the immune system. This is what Roche licensed.
• The STING pathway — a switch in innate immunity that can be turned up (agonists, to attack tumours) or down (antagonists, to calm inflammatory disease). Curadev has out-licensed both a STING agonist to Takeda and a STING antagonist programme to Bayer.

Its customers are not patients or hospitals. They are the world’s largest drug makers, who pay Curadev for the intellectual property and the early science, then fund the expensive late-stage development themselves.

The origin: a lab inside IIT Kanpur

Curadev was co-founded in 2010 by Arjun Surya and Manish Tandon. Surya, who holds the dual role of chief executive and chief scientific officer, had spent decades assessing drug molecules across therapeutic areas before starting the company. The founding bet was unusual for India: rather than making generics or running a contract-research shop for hire, Curadev would do original target discovery, the high-risk, high-reward front end of the drug industry that had largely been the preserve of Boston and Basel.

The founding insight came with a very Indian workaround for the capital problem. Original discovery needs expensive chemistry labs, and Curadev did not have Western venture money. So it incubated its drug-discovery chemistry labs inside the bio-incubator at the Indian Institute of Technology, Kanpur, using shared academic infrastructure to keep early costs down. That decision, to borrow world-class lab space rather than build it, is what let a self-funded team attempt frontier science on a shoestring.

The struggle years

Curadev’s difficulty was never a lack of ideas. It was time and cash. Drug discovery runs on a brutal clock: a molecule can take a decade to reach patients, and most never do. For a company without a big venture round, every year of research had to be paid for somehow before any partner had signed a cheque.

The early history is a string of partnerships stitched together to keep the lights on. Before the Roche deal made its name, Curadev had already worked with partners including Endo and Medivation, and it signed a drug-discovery collaboration with Karyopharm under which Curadev would take a target through to Phase 1 before handing it over. Each of these kept research funded, but none was transformational, and financial terms were rarely disclosed, leaving the company in the long, quiet grind that defines pre-clinical biotech. There was no product to sell, no revenue line that looked like a normal company’s, and a constant risk that a lead molecule would simply fail in testing and take years of work with it.

The turning point: the Roche deal

On 20 April 2015, Curadev announced a research collaboration and exclusive worldwide licence with Roche for CRD1152, a small-molecule dual inhibitor of the IDO1 and TDO enzymes, both of which tumours exploit to dodge the immune system. The terms, reported consistently by Fierce Biotech, GEN, PharmaTimes and C&EN, were transformational for an Indian startup: $25 million (about ₹240 crore) up front, up to $530 million in development and sales milestones, and escalating royalties that could reach double digits, for a headline value of up to $555 million.

The numbers on either side of that day tell the story. Before it, Curadev was a self-funded discovery shop with no marquee validation. After it, one of the world’s most respected oncology companies had staked a nine-figure sum on a molecule invented in Noida. It put Curadev on the global immuno-oncology map and, just as importantly, gave it the cash and the credibility to keep discovering. The milestone headline should not be confused with money in the bank, though: the $530 million was contingent on hitting future development and sales targets, and the guaranteed cash was the $25 million up front.

The money behind it

Curadev’s funding story is the opposite of a typical venture-backed startup. It never raised a large, headline-grabbing equity round; instead it funded itself through non-dilutive grants and, above all, through licensing deals. The shape of it:

• Equity funding: total of roughly $4.17 million, classed as seed-stage, per aggregator profiles — tiny for a company of its scientific ambition.
• Early institutional support: India’s Biotechnology Industry Research Assistance Council (BIRAC) under the Department of Biotechnology, the SIDBI-linked incubation centre, and the World Bank Group are named among early backers.
• Founders’ own capital: the company remains founder-controlled, with Arjun Surya and Manish Tandon as directors and shareholders; paid-up capital is a modest ₹1.26 crore against authorised capital of ₹2.5 crore (Tofler).
• The real fuel — licensing income: upfronts, research funding and milestone payments from Roche, Takeda and Bayer have effectively substituted for venture rounds.

There is no publicly reported post-money valuation for Curadev, which is itself telling: this is a company that chose partnership cash over dilution.

How it makes money

Curadev runs an out-licensing model. It spends money discovering and de-risking molecules, then sells the rights to partners in a structure that typically has three parts. Where the margin sits is easy to misread, so it helps to break the mechanics down:

• Upfront payment: guaranteed cash on signing — for example, the $25 million from Roche in 2015.
• Research funding: the partner often pays for continued lab work during a collaboration term, as in the Bayer STING-antagonist deal.
• Milestones: staged payments triggered only if the drug hits pre-clinical, clinical or sales targets — the bulk of any headline number, and the part most likely never to be paid if a molecule fails.
• Royalties: a percentage of eventual net sales — double-digit in the Roche deal, single-digit in the Bayer deal — which only arrive if a product reaches the market years later.

The part people get wrong is treating the milestone headline as revenue. A deal “worth up to $555 million” books only the upfront and any milestones actually achieved; the rest is optionality. Curadev’s costs, meanwhile, are overwhelmingly R&D and scientific salaries, which is why a company with billion-rupee deal headlines can still show a modest revenue line and a shrinking net worth in a heavy-investment year.

The numbers

Because Curadev is private and its income is lumpy licensing revenue rather than product sales, public sources do not break out a clean multi-year profit-and-loss statement. What is verifiable is shown below, in ₹ crore.

Tracxn puts FY25 revenue growth at about 24% over the prior year. The sharp fall in net worth reported for FY24 is consistent with a company spending heavily on its own clinical programme rather than one in distress — Curadev was, in that period, funding a first-in-human cancer trial. Set against the deal headlines, the scale is worth stating plainly: FY25 revenue of ₹14.1 crore is about $1.5 million, while the 2015 Roche pact alone was headlined at up to $555 million (about ₹5,300 crore). The first is money earned; the second is money that could be earned if the science works.

Where the money comes from

Curadev’s revenue is not a retail or geographic split — it comes almost entirely from a handful of licensing relationships with multinational pharma, and the surprise is how much of the company’s value sits in deals rather than sales. The programmes that have driven its income:

• Roche — IDO1/TDO (announced 20 April 2015): CRD1152, $25 million upfront, up to $530 million in milestones, double-digit royalties (Fierce Biotech, GEN, PharmaTimes).
• Takeda — STING agonist (announced 8 May 2019): licence to CRD5500, a small-molecule STING agonist; financial terms undisclosed (Curadev/PR Newswire, Business Today).
• Bayer — STING antagonist (announced 23 March 2020): research collaboration and licence for lung, cardiovascular and inflammatory disease; upfront plus research funding, milestones of potentially over €250 million and single-digit royalties (Pharmaceutical Technology, BioSpectrum Asia, Bayer).
• Earlier partners: Endo (from which Curadev received a first milestone in an immuno-oncology collaboration) and Karyopharm.

The geography is inverted from a normal Indian company: the science is done in Noida, but almost all the money originates from Basel, Osaka and Leverkusen.

The risks

Curadev’s model is elegant but exposed. Three concrete risks stand out, each with a clear mechanism:

• Milestone dependence and binary science. Most of the headline deal value is contingent on molecules succeeding in trials. Drug candidates fail routinely, and a partner can quietly discontinue a licensed programme, in which case the large milestone and royalty payments simply never arrive — leaving only the upfronts already banked.
• Concentration on a few partners. With income riding on a small number of licensing relationships (Roche, Takeda, Bayer), the loss or stalling of any one programme has an outsized effect on revenue, as the lumpy, sub-₹25-crore annual revenue line already shows.
• Self-funding a clinical trial. By taking its own STING agonist, CRD3874-SI, into a Phase 1a/b study, Curadev has shifted from selling early science to spending on late-stage development itself — a far more expensive game that pressured its net worth in FY24 and needs continued licensing income or new capital to sustain if trials extend.

The takeaway

The transferable lesson from Curadev is that in capital-starved deep tech, intellectual property can be a substitute for venture funding. Where most Indian startups trade equity for cash and race to scale revenue, Curadev traded molecules for milestones, keeping ownership and letting the world’s biggest drug companies fund the expensive part. It is a slower, riskier path, and the modest revenue line proves it is not a shortcut to being a large company. But it shows that an original-science business can be built from Noida on grants, shared lab space and licensing deals, without ever raising a big round or selling a single product. The number that matters is not the $555 million headline. It is that a self-funded Indian team got a company like Roche to write the cheque at all.

Frequently asked questions

What does Curadev Pharma do?

Curadev is a Noida-based small-molecule drug-discovery company focused on immuno-oncology and inflammation. It designs and de-risks experimental cancer compounds and then out-licenses them to large pharmaceutical companies, and it has begun taking one of its own molecules into early human trials.

How much was the Curadev-Roche deal worth?

The 2015 agreement gave Roche worldwide rights to Curadev’s IDO1/TDO inhibitor CRD1152 for $25 million up front and up to $530 million in milestones, for a headline of up to $555 million (about ₹5,300 crore), plus double-digit royalties. The milestones are contingent on future development and sales targets, not guaranteed.

What is Curadev’s revenue?

Curadev reported operating revenue of about ₹14.1 crore for the year to March 2025, per Tracxn, up roughly 24% on the prior year. This is licensing and research income, not product sales; the company is private and does not sell finished medicines.

Who founded Curadev and when?

Curadev Pharma was co-founded in 2010 by Arjun Surya, its chief executive and chief scientific officer, and Manish Tandon, its finance and operations chief. Its chemistry labs were incubated inside the bio-incubator at IIT Kanpur.

Is Curadev listed on the stock market?

No. Curadev Pharma Private Limited is an unlisted private company registered with the Registrar of Companies, Delhi. It has no public share price or reported post-money valuation, and has funded itself largely through grants and licensing deals rather than large equity rounds.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Fierce Biotech — Roche–Curadev IDO1/TDO deal terms (April 2015)
• GEN (Genetic Engineering & Biotechnology News) — Roche–Curadev $555M collaboration (April 2015)
• PharmaTimes — Roche, Curadev sign $555m cancer immunotherapy deal (April 2015)
• C&EN — Roche and Curadev sign IDO1/TDO pact (April 2015)
• PR Newswire / Business Today (PTI) — Curadev licences STING agonist CRD5500 to Takeda (May 2019)
• Pharmaceutical Technology / BioSpectrum Asia / Bayer — Bayer–Curadev STING antagonist deal, milestones over €250 million (March 2020)
• PR Newswire — Curadev CRD3874-SI first patient treatment cycle at Memorial Sloan Kettering (February 2024)
• ClinicalTrials.gov (NCT06021626) and Memorial Sloan Kettering — Phase 1 study of CRD3874-SI (2024–2025)
• Curadev Pharma newsroom — AACR/ASCO presentations and MSK Therapeutics Accelerator expansion (2025–2026)
• Tracxn — Curadev Pharma FY25 revenue ₹14.1 crore, headcount and profile (accessed September 2026)
• Tofler — Curadev Pharma Private Limited registry data, FY24 revenue band, net-worth change, capital and directors (accessed September 2026)
• Trading Economics — USD/INR reference rate (18 September 2026)

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.